Joshua Y. Enomoto’s Post

CNBC reveales the only two ETFs in the world that have made investors money in every year over the past decade. https://lnkd.in/dHAZURXD #etfs #investing #healthcare #pharmaceuticals #stockmarketnews #europe #canada #unitedstates #businessnews #exchangetradedfunds #cnbc

New ETF, Tema Cardiovascular and Metabolic (HRTS), has been listed on Nasdaq, offering investors a chance to cash in on the Ozempic-fueled weight loss trend. The ETF contains positions in around 20 companies involved in anti-obesity and cardiovascular-related treatments, including Novo Nordisk and Eli Lilly. The popularity of thematic ETF investments has waned this year, with investors withdrawing $4.7 billion from such funds. On the other hand, GLP-1 drugs have had a significant impact on the biopharmaceutical space, with Novo Nordisk becoming Europe's largest company and Eli Lilly climbing to be among the top 10 S&P 500 companies. #ETF #Ozempic #WeightLoss #Investing

\*\*Investing in HSA Accounts: Maximizing Potential for Growth\*\* # Shares of Viking Therapeutics: An Opportunity for Growth in the Weight-Loss Drug Market \*2024 has seen Viking Therapeutics soar, opening doors to weight-loss drug market success!\* 💪💼📈 In recent times, Viking Therapeutics has emerged as a star player in the biotech industry, poised to revolutionize the weight-loss drug market. With a surge in share prices, this presents a golden opportunity for investors looking to grow their Health Savings Account \(HSA\) portfolios. 🚀 \*\*Summary:\*\* Viking Therapeutics is on an incredible growth trajectory in 2024 as it prepares to enter the weight-loss drug market. This biotech company's innovative approach and promising drug pipeline have caught the attention of investors worldwide, resulting in skyrocketing share prices. By investing strategically in Viking Therapeutics, individuals can ride the wave of this exciting attainment and potentially benefit from substantial returns. As Viking Therapeutics seeks to address the growing demand for effective weight-loss solutions, investors have the chance to align their financial goals with contributing to a healthier world. # Don't Miss Out on the Health & Wealth Revolution! Act Now! Seize this opportunity to invest in Viking Therapeutics and grow your HSA account exponentially. Join the movement towards better health, wealth, and wellness by investing in this groundbreaking company. 💼💰💪 With the potential for significant growth and positive impacts in the healthcare industry, it's crucial not to let fear of missing out hold you back. Take action today, diversify your investment portfolio, and unlock the potential of your HSA funds. #hashtags: #hsa #investing #healthcare #health #family #wellness CTA: Don't wait! Invest in Viking Therapeutics now and be part of the revolution! 🌟💼💪

In the midst of a positive uptick in the S&P/ASX 200 Index, certain stocks like IDP Education, JB Hi-Fi, PYC Therapeutics, and Renascor Resources have taken a contrasting path. 📉 What's driving the decline? A mix of analyst downgrades, competitive market pressures, and investor reactions to trial updates have all played a role, spotlighting the complex web of factors that influence share prices. 🛠️ Understanding these market dynamics is crucial for investors aiming to navigate the volatile currents of the stock market. Keep abreast of analyst insights and industry updates to make informed investment decisions. 💡 Read the full analysis and gain a deeper understanding of today's ASX market movers: https://lnkd.in/gnp9Q-pd #ASX #Investing #StockMarket #MarketAnalysis #IDPEducation #JBHiFi #PYCTherapeutics #RenascorResources

Immuron (NASDAQ:IMRN, ASX:IMC) has received a bull case valuation of A$0.35 and a base case valuation of A$0.25 from Pitt Street Research in a report. The analysts highlight that the key catalysts for realising this potential shareholder value are the advancement of the company’s clinical-stage assets through the clinic with the end goal of bringing these assets to market. Immuron’s shares are currently trading on the ASX at A$0.072 with a market cap of A$17.1 million. More at http://ow.ly/VZUb104ZLsQ #NASDAQ #ASX #IMRN #IMC #Proactive #ProactiveInvestors #Immuron #Healthcare #Pharma

The DNB//Back Bay Partnership’s #MarketUpdate report for the week ending April 19th is now available. Highlights include:    ➡️ Bearish sentiment, driven by geopolitical tensions and rate policy uncertainty, resulted in US equities continuing their decline this week    ➡️ Intra-Cellular Therapies utilized a positive Phase 3 data readout on their drug Caplyta, which is currently being tested in major depressive disorder (MDD), as a catalyst for a $500M follow-on offering led by J.P. Morgan    ➡️ Metsera made headlines by coming out of stealth and launching with a $290M financing, hoping to challenge Novo Nordisk and Eli Lilly and Company in the red-hot space of GLP-1 agonist space for weight-loss drugs     Read the full update here: https://bit.ly/3UqmFIk     #healthcaremarket #investmentbanking #corporatebanking #marketsinc #markettrends #data #financing #majordepressivedisorder #weightloss #GLP1 #BBLSA #DNB  

Heard about concerns about the low pH of OTC injections causing damage to citrus trees? Read the details of research done on the topic from Tom Johnson, the owner of TJ BioTech, in our blog: https://lnkd.in/eq6PUEe3 #FloridaCitrus

Discover the latest trends in early-stage biopharma investments with our comprehensive report, "Investment Trends in Early-Stage Biopharma: A Beacon Data Perspective." From Series A financing peaks to the dominance of biologicals and the resurgence of biopharma IPOs, get all the insights you need to stay ahead in the market. 📥 Download your free copy today! 👉 https://ter.li/wtpcs3 #Biopharma #InvestmentTrends #SeriesAFinancing #BeaconData #MarketInsights #InvestmentStrategy

Only Put Off Until Tomorrow What You Are Willing to Die Having Left Undone Zevra Therapeutics: Q2 Earnings Snapshot 💼 H1: Only Put Off Until Tomorrow What You Are Willing to Die Having Left Undone 💰 H2: Seize the Opportunity! Invest in Zevra Therapeutics Now! 🚀 Don't Miss Out! Summary: Zevra Therapeutics, a leading healthcare company, has released its Q2 earnings report and it's an impressive one. The company has experienced significant growth in revenue and profit during the second quarter, showcasing their strong performance in the healthcare industry. As an experienced investment advisor, I highly recommend considering Zevra Therapeutics as a potential investment opportunity for your Health Savings Account (HSA). With a commitment to improving health and well-being, Zevra Therapeutics has positioned itself as a leader in the healthcare sector. Their robust financial performance in Q2 reflects their dedication and innovation in developing cutting-edge therapies and treatments. Investing in Zevra Therapeutics not only aligns with your financial goals but also contributes to the advancement of healthcare solutions. Seize this opportunity to invest in Zevra Therapeutics and capitalize on their growth potential. By including Zevra Therapeutics in your HSA investment portfolio, you can benefit from the flourishing healthcare industry while prioritizing your family's well-being. Act now to avoid the Fear of Missing Out (FOMO) and secure a prosperous future. #hsa #investing #healthcare #health #family #wellness 🏥📈✨👪💪

Only put off until tomorrow what you are willing to die having left undone. Amicus Therapeutics: Q2 Earnings Snapshot Amicus Therapeutics, a leading biotechnology company focused on rare and orphan diseases, recently released its Q2 earnings report. The company reported strong financial results, exceeding market expectations and showcasing its commitment to innovation and growth in the healthcare sector. Summary: - Amicus Therapeutics outperformed analysts' predictions in Q2, demonstrating its ability to capitalize on opportunities in the rare disease market. - The company reported robust revenue growth driven by the success of its existing drug portfolio and new product launches. - Strong financial performance has positioned Amicus Therapeutics for further expansion and investment in cutting-edge research and development initiatives. - The market response to Amicus Therapeutics' Q2 earnings suggests confidence in the company's long-term growth prospects and its potential to deliver value to investors. Don't miss out on the opportunity to invest in a company that is at the forefront of advancing treatments for rare diseases. Investing in Amicus Therapeutics not only aligns with your financial goals but also supports the well-being of individuals and families affected by these conditions. Take action now to secure your future and contribute to a healthier world. #hsa #investing #healthcare #health #family #wellness 💪💼📈💰💊🌍